Multimodal treatment in operable stage III non-small cell lung cancer using the new TNM staging classification version 8: Long term results of a pooled analysis of three SAKK trials.

Martin Frueh,Daniel Betticher,Roger Stupp,Alexandros Xyrafas,Solange Peters,Hans-Beat Ris,Adrian F. Ochsenbein,Ralph A. Schmid,Rolf A. Stahel,Walter Weder,Matthias Guckenberger,Sacha I. Rothschild,Didier Lardinois,Nicolas Mach,Michael Mark,Oliver Gautschi,Sandra Thierstein,Christine Biaggi Rudolf,Miklos Pless

Multimodal treatment in operable stage III non-small cell lung cancer using the new TNM staging classification version 8: Long term results of a pooled analysis of three SAKK trials.

2018

Martin Frueh
Daniel Betticher
Roger Stupp
Alexandros Xyrafas
Solange Peters
Hans-Beat Ris
Adrian F. Ochsenbein
Ralph A. Schmid
Rolf A. Stahel
Walter Weder
Matthias Guckenberger
Sacha I. Rothschild
Didier Lardinois
Nicolas Mach
Michael Mark
Oliver Gautschi
Sandra Thierstein
Christine Biaggi Rudolf
Miklos Pless

8531Background: The impact of the 8th edition of the TNM staging system on the optimal treatment choice and the best treatment strategy for stage III non-small cell lung cancer (NSCLC) is unclear. ...

Keywords:

Pathology
Oncology
Stage III Non-Small Cell Lung Cancer
TNM staging classification
Internal medicine
Medicine
treatment strategy
TNM staging system
pooled analysis
long term results
multimodal treatment
optimal treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations